Stock Watch: AstraZeneca And Clovis Diverge In Oncology Sales Recovery
Sales And Marketing Spending Correlates With Revenue Performance
Executive Summary
AstraZeneca’s controversial switch to for-profit COVID-19 vaccine pricing and the costs of the Alexion acquisition clouded its strength in oncology. Meanwhile, Clovis's tight grip on its marketing purse strings may have hit revenue recovery.
You may also be interested in...
Stock Watch: Big Trouble In Small Biotech
While the stock prices of a few biotech companies have advanced significantly as a result of their pandemic efforts, a broad biotech stock index has underperformed the pharmaceutical index. Why?
AstraZeneca Signs First COVID-19 Vaccine For-Profit Deals
AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.
Stock Watch: All Roads Lead Back To Pricing In Biogen And J&J’s Third-Quarter Earnings
Johnson & Johnson’s divisional recoveries were in contrast to the declines of Biogen’s franchises but both companies had a competitive pressure and a drug pricing issue.